ファブリー病治療の世界市場レポート 2025年

ファブリー病治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.8％で32億米ドルに成長します。予測期間の成長は、この疾患の有病率の増加、認知度と診断率の上昇、ヘルスケアインフラの拡大、希少疾患研究への投資の増加、患者の意識の高まり、償還政策の拡大に起因すると考えられます。予測期間における主な動向としては、遺伝子治療の進歩、酵素補充療法の進歩、診断技術の進歩、新規治療法の進歩、患者管理のためのデジタルヘルス技術の統合などが挙げられます。

ファブリー病治療市場の成長は、腎疾患の有病率の増加によって牽引されると予想されます。腎疾患（腎臓病）は、腎臓の機能に影響を及ぼす病態を包含し、遺伝的要因、ライフスタイルの選択、環境の影響、基礎的な健康問題などが原因で増加傾向にあります。ファブリー病は、特に腎細胞内のグロボトリアオシルセラミド（Gb3）の蓄積によって引き起こされ、腎臓の損傷と機能障害をもたらします。このことは、腎臓に関連した合併症を予防するための早期発見と介入が緊急に必要であることを強調しています。例えば、オーストラリア統計局の最近のデータでは、過去10年間で腎臓病患者が0.2％増加し、2022年には24万6,200人（人口の1.0％）が罹患することが明らかになっており、腎疾患の有病率のエスカレートとファブリー病治療市場への影響が強調されています。

ファブリー病治療市場の主なプレイヤーは、革新的で持続可能な方法を通じて、治療効果を高め、コストを削減し、患者の転帰を改善するために、植物細胞ベースの治療法を積極的に開発しています。ファブリー病に対する植物細胞ベースの治療には、ファブリー病患者に見られる欠損酵素を生産するために植物細胞を使用することが含まれます。これらの植物由来酵素は、体内で欠乏または欠損した酵素を補う治療オプションとして機能し、症状の緩和と患者の全体的な健康増進を目指します。例えば、Chiesi Global Rare Diseases社とProtalix BioTherapeutics社が開発した酵素補充療法であるELFABRIOは、2023年5月に承認されました。エルファブリオは、植物細胞培養で生産された組換えヒトa-ガラクトシダーゼA酵素を利用し、半減期を大幅に延長するためにPEG化で修飾されています。この革新的な治療アプローチは、治療回数を減らし、利便性を高め、症状管理を改善し、最終的にファブリー病患者のQOLを向上させる。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ファブリー病治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のファブリー病治療市場：成長率分析
• 世界のファブリー病治療市場の実績：規模と成長, 2019-2024
• 世界のファブリー病治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界ファブリー病治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のファブリー病治療市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 基質還元療法
• 酵素補充療法
• シャペロン治療
• その他の治療法
• 世界のファブリー病治療市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口経路
• 静脈内投与
• 世界のファブリー病治療市場病気の重症度別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 古典的ファブリー病
• 晩発性ファブリー病
• 世界のファブリー病治療市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のファブリー病治療市場基質還元療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ミガラスタット塩酸塩（ガラフォールド）
• その他の基質還元療法
• 世界のファブリー病治療市場酵素補充療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アガルシダーゼベータ（ファブラザイム）
• アガルシダーゼアルファ（リプラガル）
• その他の酵素補充療法
• 世界のファブリー病治療市場、シャペロン治療のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ミガラスタット塩酸塩（ガラフォールド）
• 世界のファブリー病治療市場、その他の治療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 遺伝子治療
• 治療

第7章 地域別・国別分析

• 世界のファブリー病治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のファブリー病治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ファブリー病治療市場：競合情勢
• ファブリー病治療市場：企業プロファイル
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • GSK plc Overview, Products and Services, Strategy and Financial Analysis
  • Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • CHIESI Farmaceutici S.p.A. Overview, Products and Services, Strategy and Financial Analysis
  • Ultragenyx Pharmaceutical Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Amicus Therapeutics Inc.
• JCR Pharmaceuticals Co. Ltd.
• Sangamo Therapeutics Inc.
• Idorsia Pharmaceuticals Ltd.
• Centogene N.V.
• Protalix BioTherapeutics
• Avrobio Inc.
• ISU Abxis
• Synageva BioPharma Corp.
• Greenovation Biotech GmbH
• CANbridge Pharmaceuticals
• Freeline
• 4D Molecular Therapeutics
• Abeona Therapeutics Inc.
• GC Biopharma Corporation

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ファブリー病治療市場2029：新たな機会を提供する国
• ファブリー病治療市場2029：新たな機会を提供するセグメント
• ファブリー病治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Fabry disease stems from a deficiency in alpha-galactosidase A, an enzyme crucial for breaking down globotriaosylceramide (Gb3 or GL-3) fat. This results in Gb3 accumulation within cells, prompting symptoms such as pain, kidney issues, heart complications, and strokes. Treatment aims to curtail Gb3 buildup, manage symptoms, slow organ damage, and enhance patients' quality of life.

The fabry disease treatment landscape includes substrate reduction therapy, enzyme replacement therapy, chaperone interventions, among others. Substrate reduction therapy (SRT) targets the reduction of specific substances in the body linked to fabry disease. These therapies can be administered orally or intravenously and cater to varying disease severities such as classic and late-onset fabry disease. Distribution channels encompass hospital, retail, and online pharmacies.

The fabry disease treatment market research report is one of a series of new reports from The Business Research Company that provides fabry disease treatment market statistics, including the fabry disease treatment industry global market size, regional shares, competitors with fabry disease treatment market share, detailed fabry disease treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the fabry disease treatment industry. These fabry disease treatment market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The fabry disease treatment market size has grown strongly in recent years. It will grow from $2.09 billion in 2024 to $2.28 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to increasing awareness and diagnosis rates, increasing adoption of enzyme replacement therapies, increasing use of chaperone therapies, increasing healthcare infrastructure, rise in investment in rare disease research, increasing population, and increasing regulatory incentives for orphan drugs.

The fabry disease treatment market size is expected to see strong growth in the next few years. It will grow to $3.2 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to increasing prevalence of the disease, rising awareness and diagnosis rates, expanding healthcare infrastructure, growing investment in rare disease research, growing patient awareness, and expanding reimbursement policies. Major trends in the forecast period include advancements in gene therapy, advancements in enzyme replacement therapies, advancements in diagnostic techniques, advancements in novel therapies, and integration of digital health technologies for patient management.

The growth of the Fabry disease treatment market is expected to be driven by the increasing prevalence of renal diseases. Renal diseases, or kidney diseases, encompass conditions that affect kidney function and are on the rise due to genetic factors, lifestyle choices, environmental influences, and underlying health issues. Fabry disease, specifically caused by the buildup of globotriaosylceramide (Gb3) in kidney cells, results in kidney damage and dysfunction. This emphasizes the urgent need for early detection and intervention to prevent kidney-related complications. For instance, recent data from the Australian Bureau of Statistics revealed a 0.2% increase in kidney disease cases over the past decade, with 246,200 people (1.0% of the population) affected in 2022, highlighting the escalating prevalence of renal diseases and their impact on the fabry disease treatment market.

Key players in the Fabry disease treatment market are actively developing plant cell-based therapies to enhance treatment efficacy, reduce costs, and improve patient outcomes through innovative and sustainable methods. Plant cell-based treatments for fabry disease involve using plant cells to produce deficient enzymes found in individuals with fabry disease. These plant-derived enzymes serve as a therapeutic option to replace the missing or defective enzymes in the body, aiming to alleviate symptoms and enhance patients' overall health. For example, ELFABRIO, an enzyme replacement therapy developed by Chiesi Global Rare Diseases and Protalix BioTherapeutics Inc., was approved in May 2023. ELFABRIO utilizes recombinant human a-Galactosidase-A enzyme produced in plant-cell culture and modified with PEGylation to extend its half-life significantly. This innovative treatment approach reduces treatment frequency, increases convenience, and improves symptom management, ultimately enhancing the quality of life for fabry disease patients.

In March 2024, CENTOGENE extended its partnership with Takeda Pharmaceutical Company Limited, a leader in developing therapies for lysosomal storage disorders (LSDs) such as fabry disease. This collaboration ensures continued access to diagnostic testing for patients globally, improving patient access to rapid and accurate diagnostics for LSDs, including fabry disease.

Major companies operating in the fabry disease treatment market are Sanofi S.A., GSK plc, Takeda Pharmaceutical Company Limited, CHIESI Farmaceutici S.p.A., Ultragenyx Pharmaceutical Inc., Amicus Therapeutics Inc., JCR Pharmaceuticals Co. Ltd., Sangamo Therapeutics Inc., Idorsia Pharmaceuticals Ltd., Centogene N.V., Protalix BioTherapeutics, Avrobio Inc., ISU Abxis, Synageva BioPharma Corp., Greenovation Biotech GmbH, CANbridge Pharmaceuticals, Freeline, 4D Molecular Therapeutics, Abeona Therapeutics Inc., GC Biopharma Corporation

North America was the largest region in the fabry disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fabry disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the fabry disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The fabry disease treatment market consists of revenues earned by entities by providing services such as diagnosis and screening, enzyme replacement therapy, gene therapy, disease management programs, and patient education and support. The market value includes the value of related goods sold by the service provider or included within the service offering. The Fabry disease treatment market also includes sales of Agalsidase alfa, Agalsidase beta, and Migalastat. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Fabry Disease Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on fabry disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for fabry disease treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The fabry disease treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Substrate Reduction Therapy; Enzyme Replacement Therapy; Chaperone Treatment; Other Treatments
• 2) By Route Of Administration: Oral Route; Intravenous Route
• 3) By Disease Severity: Classic Fabry Disease; Late-Onset Fabry Disease
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Substrate Reduction Therapy: Migalastat Hydrochloride (Galafold); Other Substrate Reduction Therapies
• 2) By Enzyme Replacement Therapy: Agalsidase Beta (Fabrazyme); Agalsidase Alfa (Replagal); Other Enzyme Replacement Therapies
• 3) By Chaperone Treatment: Migalastat Hydrochloride (Galafold)
• 4) By Other Treatments: Gene Therapy; Symptomatic Treatment
• Companies Mentioned: Sanofi S.A.; GSK plc; Takeda Pharmaceutical Company Limited; CHIESI Farmaceutici S.p.A.; Ultragenyx Pharmaceutical Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Fabry Disease Treatment Market Characteristics

3. Fabry Disease Treatment Market Trends And Strategies

4. Fabry Disease Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Fabry Disease Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Fabry Disease Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Fabry Disease Treatment Market Growth Rate Analysis
• 5.4. Global Fabry Disease Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Fabry Disease Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Fabry Disease Treatment Total Addressable Market (TAM)

6. Fabry Disease Treatment Market Segmentation

• 6.1. Global Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Substrate Reduction Therapy
• Enzyme Replacement Therapy
• Chaperone Treatment
• Other Treatments
• 6.2. Global Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Route
• Intravenous Route
• 6.3. Global Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Classic Fabry Disease
• Late-Onset Fabry Disease
• 6.4. Global Fabry Disease Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.5. Global Fabry Disease Treatment Market, Sub-Segmentation Of Substrate Reduction Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Migalastat Hydrochloride (Galafold)
• Other Substrate Reduction Therapies
• 6.6. Global Fabry Disease Treatment Market, Sub-Segmentation Of Enzyme Replacement Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Agalsidase Beta (Fabrazyme)
• Agalsidase Alfa (Replagal)
• Other Enzyme Replacement Therapies
• 6.7. Global Fabry Disease Treatment Market, Sub-Segmentation Of Chaperone Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Migalastat Hydrochloride (Galafold)
• 6.8. Global Fabry Disease Treatment Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gene Therapy
• Symptomatic Treatment

7. Fabry Disease Treatment Market Regional And Country Analysis

• 7.1. Global Fabry Disease Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Fabry Disease Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Fabry Disease Treatment Market

• 8.1. Asia-Pacific Fabry Disease Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Fabry Disease Treatment Market

• 9.1. China Fabry Disease Treatment Market Overview
• 9.2. China Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Fabry Disease Treatment Market

• 10.1. India Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Fabry Disease Treatment Market

• 11.1. Japan Fabry Disease Treatment Market Overview
• 11.2. Japan Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Fabry Disease Treatment Market

• 12.1. Australia Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Fabry Disease Treatment Market

• 13.1. Indonesia Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Fabry Disease Treatment Market

• 14.1. South Korea Fabry Disease Treatment Market Overview
• 14.2. South Korea Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Fabry Disease Treatment Market

• 15.1. Western Europe Fabry Disease Treatment Market Overview
• 15.2. Western Europe Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Fabry Disease Treatment Market

• 16.1. UK Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Fabry Disease Treatment Market

• 17.1. Germany Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Fabry Disease Treatment Market

• 18.1. France Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Fabry Disease Treatment Market

• 19.1. Italy Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Fabry Disease Treatment Market

• 20.1. Spain Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Fabry Disease Treatment Market

• 21.1. Eastern Europe Fabry Disease Treatment Market Overview
• 21.2. Eastern Europe Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Fabry Disease Treatment Market

• 22.1. Russia Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Fabry Disease Treatment Market

• 23.1. North America Fabry Disease Treatment Market Overview
• 23.2. North America Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Fabry Disease Treatment Market

• 24.1. USA Fabry Disease Treatment Market Overview
• 24.2. USA Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Fabry Disease Treatment Market

• 25.1. Canada Fabry Disease Treatment Market Overview
• 25.2. Canada Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Fabry Disease Treatment Market

• 26.1. South America Fabry Disease Treatment Market Overview
• 26.2. South America Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Fabry Disease Treatment Market

• 27.1. Brazil Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Fabry Disease Treatment Market

• 28.1. Middle East Fabry Disease Treatment Market Overview
• 28.2. Middle East Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Fabry Disease Treatment Market

• 29.1. Africa Fabry Disease Treatment Market Overview
• 29.2. Africa Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Fabry Disease Treatment Market Competitive Landscape And Company Profiles

• 30.1. Fabry Disease Treatment Market Competitive Landscape
• 30.2. Fabry Disease Treatment Market Company Profiles
  • 30.2.1. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. GSK plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. CHIESI Farmaceutici S.p.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Ultragenyx Pharmaceutical Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Fabry Disease Treatment Market Other Major And Innovative Companies

• 31.1. Amicus Therapeutics Inc.
• 31.2. JCR Pharmaceuticals Co. Ltd.
• 31.3. Sangamo Therapeutics Inc.
• 31.4. Idorsia Pharmaceuticals Ltd.
• 31.5. Centogene N.V.
• 31.6. Protalix BioTherapeutics
• 31.7. Avrobio Inc.
• 31.8. ISU Abxis
• 31.9. Synageva BioPharma Corp.
• 31.10. Greenovation Biotech GmbH
• 31.11. CANbridge Pharmaceuticals
• 31.12. Freeline
• 31.13. 4D Molecular Therapeutics
• 31.14. Abeona Therapeutics Inc.
• 31.15. GC Biopharma Corporation

32. Global Fabry Disease Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Fabry Disease Treatment Market

34. Recent Developments In The Fabry Disease Treatment Market

35. Fabry Disease Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Fabry Disease Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Fabry Disease Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Fabry Disease Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer